General Dynamics Corporation (GD), headquartered in Reston, Virginia, operates as a global aerospace and defense company. Valued at $92.4 billion by market cap, the company offers a broad portfolio of products and services in business aviation, combat vehicles, weapons systems, munitions, shipbuilding design and construction, information systems, and technologies. The defense giant is expected to announce its fiscal third-quarter earnings for 2025 before the market opens on Friday, Oct. 24. Ahead of the e ...

Core Insights - General Dynamics reported revenue of $13.04 billion for the quarter ended June 2025, reflecting an 8.9% increase year-over-year and a surprise of +5.62% over the Zacks Consensus Estimate of $12.35 billion [1] - Earnings per share (EPS) for the quarter was $3.74, up from $3.26 in the same quarter last year, with an EPS surprise of +4.18% compared to the consensus estimate of $3.59 [1] Revenue Performance by Segment - Technologies segment generated revenue of $3.48 billion, exceeding the six-analyst average estimate of $3.25 billion, with a year-over-year change of +5.5% [4] - Marine Systems reported revenue of $4.22 billion, significantly above the $3.74 billion average estimate, representing a year-over-year increase of +22.2% [4] - Combat Systems achieved revenue of $2.28 billion, slightly above the six-analyst average estimate of $2.26 billion, with a minimal year-over-year decline of -0.2% [4] - Aerospace revenue was $3.06 billion, in line with the six-analyst average estimate of $3.07 billion, showing a year-over-year increase of +4.2% [4] Operating Earnings Performance - Aerospace operating earnings were reported at $403 million, slightly below the average estimate of $404.44 million [4] - Combat Systems operating earnings reached $324 million, exceeding the average estimate of $317.41 million [4] - Technologies operating earnings were $332 million, surpassing the average estimate of $298 million [4] - Marine Systems operating earnings were $291 million, significantly above the average estimate of $254.82 million [4] - Corporate segment reported operating earnings of -$45 million, worse than the average estimate of -$14.05 million [4] Stock Performance - General Dynamics shares returned +5.9% over the past month, matching the Zacks S&P 500 composite's +5.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - L.B. Foster reported a revenue of $97.79 million for the quarter ended March 2025, reflecting a decline of 21.3% year-over-year [1] - The company's EPS was -$0.20, a significant drop from $0.08 in the same quarter last year, indicating a substantial earnings miss [1] - The revenue fell short of the Zacks Consensus Estimate by 14.53%, which was projected at $114.41 million [1] - The EPS surprise was notably negative at -2100.00% compared to the consensus estimate of $0.01 [1] Financial Performance Metrics - Net Sales in Rail, Technologies, & Services amounted to $54.02 million, below the average estimate of $73.97 million from two analysts [4] - Net Sales in Infrastructure Solutions reached $43.78 million, slightly above the two-analyst average estimate of $40.43 million [4] - Segment Operating Income for Infrastructure Solutions was reported at -$0.44 million, better than the average estimate of -$0.63 million [4] - Segment Operating Income for Rail, Technologies, and Services was $0.14 million, significantly lower than the average estimate of $4.59 million [4] Stock Performance - L.B. Foster's shares have returned +10.1% over the past month, compared to a +11.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - Harvard Bioscience, Inc. will announce its financial results for Q1 2025 on May 12, 2025, before market opens, followed by a conference call at 8:00 a.m. Eastern Time [1] Company Overview - Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that facilitate advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production, and preclinical testing [3] - The company serves a diverse customer base, including academic institutions, government laboratories, and leading pharmaceutical, biotechnology, and contract research organizations globally [3] - Operations are conducted in the United States, Europe, and China, utilizing both direct and distribution channels for sales [3]